Kodiak Sciences Inc.
https://kodiak.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kodiak Sciences Inc.
Kodiak Turns Back On Tarcocimab After Two Pivotal Trial Flops In DME
The US firm’s lead antibody biopolymer conjugate asset failed to match Regeneron/Bayer’s Eylea in two Phase III diabetic macular edema studies, prompting discontinuation of the program and a reassessment of an earlier program based on the same platform technology.
Kodiak’s KSI-301 Has Narrower Path Forward After Phase II/III Failure In Wet AMD
Monthly dosing remains a possibility in wet age-related macular degeneration, though diabetic macular edema and retinal vein occlusion look more promising.
Five Pivotal Trial Read-Outs To Look Out For In Early 2022
Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.
Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD
Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Oligasis LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice